Do GLP-1 drugs cause gallbladder problems?

GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound do raise the odds of gallbladder trouble, and the signal is real enough that the FDA put it on the drug labels. But the absolute risk is small for most people, and a big chunk of it comes from the fast weight loss these drugs cause rather than the molecule itself. This guide walks through what the evidence actually shows, where it's strong, where it's shaky, and what you can do about it.

The short version, then the detail

The single best piece of evidence is a 2022 meta-analysis in JAMA Internal Medicine that pooled 76 randomized trials and more than 100,000 people. It found that being assigned to a GLP-1 drug raised the risk of gallbladder or biliary disease by about 37 percent compared with controls (He L, et al., JAMA Intern Med 2022; PMID 35344001).

Thirty-seven percent sounds scary. It isn't, in absolute terms. A relative jump like that translates to roughly 2 to 3 extra cases per 1,000 people treated for a year. The risk climbs when the dose is higher, the treatment lasts longer, and the goal is weight loss rather than blood sugar control. Below we break down the mechanism, the numbers drug by drug, and how the gallstone risk from these drugs compares to plain old crash dieting.

What "gallbladder problems" actually means

The gallbladder is a small pouch under your liver. It stores bile, the fluid your liver makes to help digest fat. When you eat, the gallbladder squeezes bile out into your gut. Problems show up when that system gets sluggish or when the bile turns to sludge and then to stones.

The terms you'll see in studies and on labels:

Cholelithiasis — gallstones. Hardened deposits of cholesterol or pigment. Many people have them and never know.
Cholecystitis — inflammation of the gallbladder, usually because a stone is blocking the exit. This one hurts and can land you in the hospital.
Biliary disease — a catch-all for problems in the bile ducts, including blockages and infection.
Cholecystectomy — surgery to remove the gallbladder. The common fix when stones cause repeated trouble.

Most gallstones never cause symptoms. The ones that matter are the stones that block something. That's the line between "I have stones on an ultrasound" and "I'm in the ER with right-upper-belly pain, fever, and nausea."

Why does this distinction matter so much for reading the drug studies? Because a trial that does routine ultrasounds will find a lot of silent stones that would never have bothered anyone. A trial that only counts people who show up with symptoms will report a much lower number. The 2022 JAMA Internal Medicine analysis pooled studies that mostly counted clinical events, not incidental ultrasound findings, which is part of why its estimate is grounded in real-world consequences rather than scan results. When you see a scary "X percent had gallstones" figure, the first question to ask is whether those were symptomatic stones or just shadows on an ultrasound.

There's also a timing pattern worth knowing. The gallbladder risk isn't spread evenly across your whole time on the drug. It clusters in the first several months, during the steepest part of the weight-loss curve. Once your weight stabilizes, the bile chemistry settles down and the elevated risk fades. This is the same pattern seen after bariatric surgery and crash diets: the danger window is the rapid-loss phase, not the maintenance phase that follows.

How GLP-1 drugs might cause it

There are two pathways, and they probably both play a role.

Pathway one: the drug slows the gallbladder directly. GLP-1 affects gut motility. It slows how fast your stomach empties, which is part of why you feel full. The same braking effect appears to reach the gallbladder, so it squeezes less often and less completely. Bile that sits still gets concentrated. Concentrated bile is where stones start.

Pathway two: fast weight loss. This is the bigger driver, and it's not unique to GLP-1 drugs. When you lose weight quickly, your body pulls cholesterol out of fat stores and dumps it into bile. The bile becomes supersaturated with cholesterol, meaning it's holding more than it can keep dissolved. The extra cholesterol crystallizes. Add a sluggish gallbladder that isn't flushing itself out, and you have the recipe for stones (Johansson K, et al. / VLCD cohort, Int J Obes 2014; PMID 23736359).

This second pathway matters for how you read the data. Rapid weight loss causes gallstones whether you do it with a GLP-1 drug, a crash diet, or bariatric surgery. So when a weight-loss trial shows more gallstones in the drug group, part of that is the drug and part is simply that the drug group lost more weight.

The evidence, graded honestly

Here's the head-to-head on the main bodies of evidence, with a frank read on how much to trust each.

Evidence source	What it found	Strength	Honest caveats
He L, et al. meta-analysis, JAMA Internal Medicine 2022 (76 randomized trials, 103,371 people)	Overall RR 1.37 (95% CI 1.23–1.52) for gallbladder/biliary disease; higher with high dose, long duration, and weight-loss use	Strongest. Pooled randomized data, large sample	Biliary events were rare overall, so subtypes had wide confidence intervals. Not every trial actively hunted for gallbladder events
FDA labels for Ozempic, Wegovy, Mounjaro, Zepbound	Acute gallbladder disease listed as a warning; cholelithiasis rates a few percent on drug vs lower on placebo	Strong as a regulatory signal	Label rates come from selected trials, not a single clean comparison
Tirzepatide safety meta-analysis, Frontiers in Endocrinology 2023 (PMID 37908750)	Composite gallbladder/biliary RR 1.97 (95% CI 1.14–3.42); individual stone/inflammation outcomes not significant alone	Moderate	The composite was significant but the pieces weren't, which means the finding is real but the sample is too small to pin down exactly which event drives it
FAERS pharmacovigilance reports (real-world adverse-event database)	Disproportionate reporting of cholecystitis and cholelithiasis with GLP-1 drugs	Weak for causation	FAERS is voluntary reporting. It shows a signal, not a rate. Subject to reporting bias and media attention
Crash-diet and bariatric-surgery literature	Rapid weight loss alone raises symptomatic gallstone risk roughly 3-fold	Strong, and important context	Tells us the weight-loss pathway is real, independent of any drug

The takeaway: the association is solidly established. The exact size for any one drug is fuzzier, because gallbladder events are uncommon and most trials weren't designed to chase them.

A word on industry funding and bias

Most of the pivotal GLP-1 trials were funded by the companies that make the drugs, Novo Nordisk and Eli Lilly. That's normal for new medications, but it's worth naming. Industry-funded trials are not designed to surface uncommon harms like gallstones; they're built to prove the drug works for its main purpose. Adverse events get collected, but the studies are usually too short and too small to nail down a rare side effect with precision.

This is exactly why the independent 2022 meta-analysis matters. Pooling 76 separate trials gets you to a sample size no single company study reaches, and the relative risk it produced (1.37) is more trustworthy than any one trial's gallbladder count. The FAERS pharmacovigilance signal adds a real-world layer, but it's the weakest link in the chain because it can't tell you a rate. When you weigh all of it together, the honest read is: the link is real and consistently shows up across data sources, but the precision is limited and the strongest single number we have is that 37 percent relative bump.

Drug-by-drug numbers

Different products report different rates, partly because of dose and partly because weight-loss doses cause more weight loss. These figures come from the FDA prescribing information and the pivotal trials.

Drug	Active ingredient	Main use	Reported gallbladder signal	Source
Ozempic	Semaglutide	Type 2 diabetes	Cholelithiasis ~1.5% (0.5 mg) and ~0.4% (1 mg) vs 0% placebo	FDA Ozempic label
Wegovy	Semaglutide (higher dose)	Weight management	Gallbladder disorders ~2.6% vs ~1.2% placebo in the STEP 1 trial	FDA Wegovy label
Mounjaro / Zepbound	Tirzepatide	Diabetes / weight	Composite gallbladder-biliary RR ~1.97; cholelithiasis ~2.5% vs ~1.0% in SURMOUNT-1	Tirzepatide meta-analysis, PMID 37908750

A pattern jumps out: the weight-management versions (Wegovy, Zepbound) show higher gallbladder rates than the lower-dose diabetes versions. That fits the weight-loss-drives-stones idea. It also means the dose isn't doing something magically harmful on its own; the bigger weight drop is doing a lot of the work.

How much of this is the drug versus the weight loss?

Honest answer: nobody has fully separated the two. The mechanism studies suggest GLP-1 has a direct gallbladder-slowing effect, so it's not purely weight loss. But the trial pattern, where higher weight loss tracks with more stones, says weight loss is a major contributor. The fair statement is "both, and we can't give you a clean percentage split." Be wary of any source that claims to know the exact breakdown. The data don't support that level of confidence.

Is GLP-1 worse than other ways to lose weight?

This is the comparison that gets lost in scary headlines. Losing weight fast causes gallstones no matter how you do it.

Weight-loss method	Symptomatic gallstone risk	Notes
Very-low-calorie diet (around 500 kcal/day)	Roughly 3 times higher than a moderate diet	Swedish cohort: 152 vs 44 events per 10,000 person-years (PMID 23736359)
Bariatric surgery	High enough that many surgeons prescribe preventive medication after the operation	Rapid, large weight loss
GLP-1 drugs	Modestly elevated (RR ~1.37 overall)	Slower, steadier weight loss than crash dieting or surgery
Slow, moderate diet (1–2 lb/week)	Lowest	The pace itself is protective

Framed this way, GLP-1 drugs don't look like an unusual villain. They cause gallstones the same way any effective weight-loss tool does, and arguably less than a crash diet because the weight comes off more gradually. The drug's direct effect is the part that pushes its risk a bit above what you'd predict from weight loss alone.

The Swedish very-low-calorie-diet cohort is the cleanest illustration. Those dieters weren't on any drug. They simply ate around 500 calories a day, lost weight fast, and their symptomatic gallstone rate ran about three times higher than people losing weight at a gentler pace (Int J Obes 2013; PMID 23736359). No GLP-1 receptor anywhere in that story. The lesson: the speed of weight loss is doing a lot of the damage, and a drug that takes weight off over months rather than weeks is, in this one respect, kinder to your gallbladder than starvation dieting.

That doesn't let the drugs off the hook entirely. The mechanism work showing direct slowing of gallbladder contraction means there's a piece of the risk that's molecular, not just metabolic. But it does reframe the question. The useful comparison isn't "GLP-1 versus doing nothing." It's "GLP-1 versus the other ways you might lose this weight," and on that scale the drugs hold up reasonably well.

Who is most at risk

The factors that raise gallbladder risk on these drugs are the same factors that raise it generally, plus a few specific to the medication:

Fast weight loss. Losing more than about 3 lb (1.5 kg) per week is the classic danger zone.
Higher doses and weight-loss indications. Wegovy and Zepbound carry higher reported rates than the diabetes-dose versions.
Longer treatment. Risk accumulated over time in the pooled trials.
Being female, older, overweight, or having a family history of gallstones. Standard gallstone risk factors stack on top.
A history of gallstones. If you've had them before, you're more likely to make more.

If several of these apply to you, it's worth a conversation with your prescriber before you start, and ultrasound if you have symptoms. For broader context on what else these drugs do, see our complete guide to GLP-1 side effects and the GLP-1 medications side effects and risks overview. Gallbladder pain can also be confused with another rare but serious GLP-1 concern, so it helps to understand the real evidence on Ozempic and pancreatitis risk too.

Warning signs to take seriously

Most gallstones stay silent. The ones that block a duct cause a textbook pattern. Get medical help if you have:

Steady, severe pain in the upper-right belly or center of the abdomen, often after a fatty meal
Pain that spreads to your right shoulder or shoulder blade
Nausea and vomiting with that pain
Fever or chills
Yellowing of the skin or eyes (jaundice)
Dark urine or pale stools

Pain that lasts more than a few hours, or comes with fever or jaundice, is an emergency. That's cholecystitis or a blocked duct, not ordinary indigestion. Don't wait it out.

How doctors diagnose and treat it

If gallbladder trouble is suspected while you're on a GLP-1 drug, the workup is the same as for anyone else. The first test is usually an abdominal ultrasound, which is quick, painless, and good at spotting stones. Blood tests check for signs of inflammation, infection, or a blocked bile duct (liver enzymes and bilirubin). If a duct blockage is the concern, doctors may order more detailed imaging like an MRCP, a special MRI of the bile ducts.

Treatment depends on what's found:

Silent stones, no symptoms. Usually left alone. Most never cause trouble, and surgery isn't justified for stones that aren't bothering you.
Recurrent painful attacks (biliary colic). The standard fix is cholecystectomy, removing the gallbladder. It's one of the most common operations in the world and people live normally without a gallbladder.
Acute cholecystitis or a blocked duct. This is urgent. It needs antibiotics, sometimes a procedure to clear the duct, and often surgery, occasionally on a hospital timeline measured in hours.

Removing the gallbladder doesn't mean stopping the GLP-1 drug. Plenty of people have a cholecystectomy and continue treatment afterward, since the stones that prompted the surgery are gone. That's a decision to make with your care team, weighing the metabolic benefits against your individual history.

One nuance for diabetes patients comparing options: the related DPP-4 inhibitor class (drugs like sitagliptin) has been studied for the same risk, and a 2022 BMJ network meta-analysis found a smaller and less consistent gallbladder signal for that class (DPP-4 inhibitors and gallbladder disease, BMJ 2022; PMID 35764326). DPP-4 inhibitors don't cause meaningful weight loss, which fits the theme that weight loss is the main driver. They're far less effective for weight and metabolic outcomes, so this isn't a reason to switch, but it does reinforce the mechanism story.

How to lower the risk

You can't make the risk zero, but you can shave it down.

Go slow. A steadier weight-loss pace is gentler on the gallbladder. This is one more reason not to chase the fastest possible results by jumping doses early. Titrating up gradually, which prescribers do anyway to limit nausea, also helps the gallbladder.

Keep some fat in your meals. Counterintuitive, but a gallbladder that never gets the signal to squeeze just sits there with stagnant bile. A little dietary fat at meals triggers contraction and keeps bile moving. Very-low-fat crash diets are part of why crash dieting causes so many stones.

Stay hydrated and keep moving. General measures, modest evidence, low downside.

Ask about ursodeoxycholic acid (UDCA) if you're high risk. UDCA is a bile acid that reduces cholesterol in bile and helps the gallbladder empty. It's well established for preventing stones during rapid weight loss and after bariatric surgery (UDCA and gallbladder emptying, Gastroenterology 1984; PMID 6329890). It is not routinely prescribed for everyone on a GLP-1 drug, and the evidence specifically in GLP-1 users is thinner than the bariatric data. But for someone with a gallstone history losing weight fast, it's a reasonable thing to raise with a doctor.

Don't stop a working drug out of fear alone. The cardiovascular and metabolic benefits of these drugs are well documented and, for most people, outweigh a small bump in gallbladder risk. The right move is monitoring and prevention, not avoidance. If you're weighing your options, our roundup of the best GLP-1 medications for weight loss and the broader GLP-1 medications side effects and risks guide can help you frame the conversation.

Where the evidence is weak

In the spirit of not overstating things:

Exact per-drug rates are uncertain. Gallbladder events are rare, so confidence intervals are wide, especially for tirzepatide where the composite was significant but individual outcomes weren't.
The drug-versus-weight-loss split is unresolved. We know both contribute. We can't hand you clean percentages.
FAERS signals are not rates. Real-world reporting databases show a flag went up, not how often the problem happens. Media coverage inflates reporting.
Prevention with UDCA in GLP-1 users specifically is under-studied. Most of the prevention evidence comes from crash diets and surgery, then gets extended to GLP-1 by analogy. Reasonable, but not the same as a trial in GLP-1 patients.

None of this changes the headline. The link is real. It's just smaller and more weight-loss-driven than alarming headlines suggest.

Frequently Asked Questions

Do GLP-1 drugs definitely cause gallbladder problems?

They raise the risk; they don't guarantee a problem. The strongest evidence, a 2022 meta-analysis of 76 randomized trials, found about a 37 percent relative increase in gallbladder or biliary disease, which works out to roughly 2 to 3 extra cases per 1,000 people treated for a year. Most people on these drugs never develop gallbladder trouble.

Is the gallstone risk from the drug itself or from losing weight fast?

Both, and the data can't fully separate them. GLP-1 appears to slow the gallbladder directly, and the fast weight loss the drugs cause independently promotes gallstones by loading bile with cholesterol. The weight-loss pathway is probably the bigger contributor, which is why the higher-dose weight-management versions show higher rates.

Which GLP-1 drug has the lowest gallbladder risk?

The lower-dose diabetes versions, like Ozempic at standard doses, report lower gallbladder rates than the higher-dose weight-loss versions like Wegovy and Zepbound. But the differences are small and the trials weren't built for clean head-to-head gallbladder comparisons, so don't pick a drug on this factor alone.

Can I prevent gallstones while on a GLP-1 medication?

You can lower the odds. Lose weight gradually, keep some fat in your meals so the gallbladder keeps contracting, and stay hydrated. If you're high risk, ask your doctor about ursodeoxycholic acid, a bile acid with good evidence for preventing stones during rapid weight loss, though it's not standard for everyone on these drugs.

When should I worry about gallbladder pain on a GLP-1 drug?

Get medical help for steady, severe pain in the upper-right or central belly, especially after fatty food, or pain that spreads to your right shoulder. Fever, chills, vomiting, or yellowing of the skin or eyes are emergencies. Those suggest a blocked duct or an inflamed gallbladder, not ordinary nausea.

This article is for general information and is not medical advice. Talk to a licensed clinician before starting, stopping, or changing any medication, and seek emergency care for severe abdominal pain, fever, or jaundice.